MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.42 -3.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.41

Max

2.52

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -38M
Müük	1.6M 11M
Kasumimarginaal	-333.127
Töötajad	144
EBITDA	-1.8M -35M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+313.2% upside

Turustatistika
By TradingEconomics
Turukapital	57M 552M
Eelmine avamishind	6.01
Eelmine sulgemishind	2.42

Uudiste sentiment

By Acuity

13%

87%

13 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2025, 16:58 UTC

Tulu

BMW Trims 2025 View, Citing Weaker Performance in China

7. okt 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. okt 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. okt 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. okt 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 20:44 UTC

Kuumad aktsiad

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. okt 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. okt 2025, 19:23 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. okt 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. okt 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. okt 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. okt 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. okt 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. okt 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. okt 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. okt 2025, 14:52 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

313.2% tõus

12 kuu keskmine prognoos

Keskmine 10.33 USD 313.2%

Kõrge 15 USD

Madal 8 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

13 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.